Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5421]

Comment: Immunotherapy combination for advanced NSCLC

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Immunotherapy combination for advanced NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

Comment: Front-line osimertinib significantly lengthens overall survival in...

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre...

Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities ( Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium )

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk...

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

Adding daratumumab to existing multiple myeloma regimen of lenalidomide...

Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA

Adding daratumumab to existing multiple myeloma regimen of lenalidomide, bortezomib and dexamethasone ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Comparative effectiveness of lenalidomide, bortezomib, and their combinations...

Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )

Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

$Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )$

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )

Real-world use of carfilzomib therapy among patients with existing...

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma...

Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK )

HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

$HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )$

More from ecancer